文献速递肝病

晚期NASH纤维化组织学与非侵入性检测与不良临床及患者报告结局的关联

The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
PubMed 文献 · Gastroenterology · 2020-12-08

研究纳入2154例晚期NASH(F3/F4)患者,评估组织学和非侵入性检测(NIT)与临床及患者报告结局(PRO)的关联。基线NIT评分及随时间变化可预测疾病进展和PRO损害,NIT评分升高与进展风险增加相关,下降则PRO改善。

要点

  • 基线NIT评分越高,晚期NASH患者疾病进展风险越高。
  • NIT评分升高与PRO损害相关,下降则PRO改善。
  • F3患者16.7%进展为肝硬化,F4患者7.3%发生临床事件。

核心结论

  • 基线NIT评分及其随时间变化是晚期NASH患者不良临床和PRO的预测因素。

研究设计与样本

  • 纳入4项司美鲁单抗和selonsertib多国临床试验的晚期NASH(F3或F4)患者,前瞻性收集肝活检、NIT和PRO。

主要发现

  • 共纳入2154例晚期NASH患者,52.5%为F4,40%男性,72%患2型糖尿病,中位随访16个月。
  • 基线F3患者中16.7%进展为肝硬化,F4患者中7.3%发生临床事件(39%腹水,24%肝性脑病)。
  • 进展患者基线NIT评分更高(所有P < .0001)。
  • 调整基线后,NIT评分升高与F3和F4组疾病进展风险增加相关(F3所有NIT P < .01;F4中ELF、NAFLD纤维化评分、FIB-4和肝硬度P < .01)。
  • NIT评分升高与PRO损害相关:ELF ≥10.43、NAFLD纤维化评分 ≥1.80、Fibrotest ≥0.54、肝硬度 ≥23.4 kPa。

关键数值与推荐

  • ELF ≥10.43、NAFLD纤维化评分 ≥1.80、Fibrotest ≥0.54、肝硬度 ≥23.4 kPa与PRO损害相关。

临床怎么用

  • 基线NIT评分及动态变化可用于预测晚期NASH患者疾病进展和PRO损害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIM: Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis (NASH). We assessed the associations between histologic and noninvasive tests (NITs) for fibrosis with clinical and patient-reported outcomes (PROs) in advanced NASH. METHODS: Patients with advanced NASH (NASH Clinical Research Network stage F3 or F4) were enrolled in 4 multinational clinical trials of simtuzumab and selonsertib. Liver biopsy samples, NIT results, and PROs (Short Form-36, Chronic Liver Disease Questionnaire-NASH, EuroQol-5D, and Work Productivity and Activity Impairment) were prospectively collected. RESULTS: A total of 2154 patients with advanced NASH were included: 52.5% with F4 NASH, 40% male, 72% with type 2 diabetes, baseline liver stiffness of 24.1 ± 14.2 kPa in F4 disease and 14.6 ± 8.0 kPa in F3 disease, baseline mean Enhanced Liver Fibrosis score of 11.4 ± 1.2 in F4 disease and 10.3 ± 1.0 in F3 disease, and a median follow-up of 16 months. Of those with baseline F3 disease, 16.7% experienced disease progression to cirrhosis, whereas for those with F4 disease, 7.3% experienced clinical events (39% ascites, 24% hepatic encephalopathy); patients who progressed had higher baseline NIT scores (all P < .0001). Adjusted for baseline levels, increases in NIT scores were also associated with increased risk of disease progression in both the F3 and F4 groups (P < .01 for all NITs in F3 and for ELF, NAFLD Fibrosis Score, Fibrosis-4 (FIB-4), and liver stiffness in F4). Higher NIT scores were found to be associated with impairment in PROs: ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest score, ≥0.54; liver stiffness, ≥23.4 kPa. During treatment, patients with decreases in NIT scores experienced improvement of their PRO scores, whereas those with increase in NIT scores had their PRO scores worsen (P < .05). CONCLUSIONS: Baseline NIT scores and their changes over time are predictors of adverse clinical and PROs in patients with advanced NASH. (ClinicalTrials.gov, Numbers NCT01672866, NCT01672879, NCT03053050, and NCT03053063).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Anstee QM, Wai-Sun Wong V, et al. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Gastroenterology. 2020. PMID: 33307033. doi:10.1053/j.gastro.2020.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。